Nautilus Biotechnology
48 articles with Nautilus Biotechnology
-
Nautilus Biotechnology to Participate in B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference
3/23/2023
Nautilus Biotechnology, Inc. today announced the company will be participating in the upcoming B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference.
-
Nautilus Biotechnology Announces “First Access Challenge” Winners
3/7/2023
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced the selection of three research proposals submitted to the First Access Challenge, a competition for furthering high-impact work in proteomics.
-
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2022 Financial Results
2/23/2023
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2022.
-
Nautilus Biotechnology to Participate in the 43rd Annual Cowen Health Care Conference
2/21/2023
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the upcoming 43rd Annual Cowen Health Care Conference.
-
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
1/26/2023
Nautilus Biotechnology, Inc. today announced it will report financial results for the fourth quarter and full year of 2022 before market open on Thursday, February 23, 2023.
-
Nautilus Biotechnology Expands to San Diego
1/26/2023
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced the opening of its new office space at University Town Center in San Diego, California.
-
Nautilus Biotechnology Partners with the Translational Genomics Research Institute (TGen) to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma (DIPG)
1/19/2023
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform, and the Translational Genomics Research Institute, part of City of Hope, announced a partnership to explore the utility of the Nautilus platform by studying specific protein targets in diffuse intrinsic pontine glioma, a rare and often fatal childhood cancer.
-
Nautilus Biotechnology Launches “First Access Challenge”
11/16/2022
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced the launch of the First Access Challenge, a research competition for high-impact work in single-molecule proteomics.
-
Nautilus Biotechnology Reports Third Quarter 2022 Financial Results
11/1/2022
Nautilus Biotechnology, Inc., a company pioneering a single molecule proteome analysis platform, reported financial results for the third quarter ended September 30, 2022.
-
Nautilus Biotechnology to Announce Third Quarter 2022 Financial Results on November 1, 2022
10/5/2022
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced it will report financial results for the third quarter 2022 before market open on Tuesday, November 1, 2022.
-
Nautilus Biotechnology to Participate in the Capital One Spatial Biology & Proteomics Summit
9/23/2022
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Capital One Spatial Biology & Proteomics Summit taking place virtually on Wednesday, September 28, 2022.
-
Nautilus Biotechnology Joins Human Proteome Organization (HUPO) Industrial Advisory Board
9/1/2022
Nautilus Biotechnology, Inc. announced it has joined the Human Proteome Organization Industrial Advisory Board.
-
Nautilus Biotechnology to Participate in the Morgan Stanley Global Healthcare Conference
8/30/2022
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.
-
New chief executive officers take the reins of companies, while chief financial officers step into their roles overseeing the finances of respective businesses and more.
-
Nautilus Biotechnology Reports Second Quarter 2022 Financial Results
8/2/2022
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis, today reported financial results for the second quarter ended June 30, 2022.
-
Nautilus Biotechnology Appoints Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development
8/1/2022
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced further expansion of its management team with the appointments of Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development.
-
Nautilus Biotechnology to Announce Second Quarter 2022 Financial Results on August 2, 2022
7/13/2022
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter 2022 before market open on Tuesday, August 2nd , 2022.
-
Nautilus Biotechnology Reports First Quarter 2022 Financial Results
5/3/2022
Nautilus Biotechnology, Inc., a company pioneering a single molecule proteome analysis, reported financial results for the first quarter ended March 31, 2022.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Nautilus Biotechnology Appoints Gwen Weld as Chief People Officer and Sheri Wilcox, Ph.D., as Vice President of Affinity Reagent Development
4/12/2022
Nautilus Biotechnology, Inc. announced the appointments of Gwen Weld as Chief People Officer and Sheri Wilcox, Ph.D., as Vice President of Affinity Reagent Development, adding further experience to its senior leadership team in its ongoing expansion of the organization.